24 completed, 11 recruiting, 6 active not recruiting, 6 terminated. 50 Phase 1, 25 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 50 | Completed 24, Recruiting 11, Active not recruiting 6, Terminated 6, Withdrawn 3 |
| Phase 2 | 25 | Completed 11, Recruiting 7, Active not recruiting 3, Terminated 3, Withdrawn 1 |
Follow TBI: new trials by email Literature Review of TBI trials Research Report on TBI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) 131I-apamistmab, Sirolimus, Campath - Sickling Disorder Due to Hemoglobin S | Phase 1 | Recruiting | Columbia University | 24 | 2025-04-28 | 2026-06-10 |
| Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation - Multiple Myeloma | Phase 1 | Recruiting | Washington University School of Medicine | 16 | 2024-12-04 | 2026-03-11 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg - SIOD, Cystinosis | Phase 1 / Phase 2 | Recruiting | Alice Bertaina | 12 | 2023-01-10 | 2023-07-17 |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 | Withdrawn | Ossium Health, Inc. | 2022-09-01 | 2026-02-24 | |
| Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia TBI, Hydroxyurea, briquilimab - Sickle Cell Anemia, Beta Thalassemia | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 40 | 2022-05-12 | 2026-03-12 |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2020-12-03 | 2026-09-17 |
| Haplo Peripheral Blood Sct In GVHD Prevention FLUDARABINE, CYCLOPHOSPHAMIDE, TBI - GVHD, AML | Phase 1 | Completed | Zachariah Michael DeFilipp | 25 | 2020-08-14 | 2025-07-20 |
| Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide - Non-Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 40 | 2020-06-16 | 2026-06-17 |
| Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Bendamustine, Cyclophosphamide - Hematopoietic and Lymphoid System Neoplasm | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 25 | 2020-03-13 | 2026-07-16 |
| TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy, Tomotherapy - Acute Leukemia, Myelodysplastic Syndrome | Phase 1 | Active not recruiting | City of Hope Medical Center | 20 | 2020-02-28 | 2026-08-05 |
| Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 16 | 2019-08-08 | 2026-06-11 |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2019-07-10 | 2026-06-22 |
| VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies Cord blood stem cells, Valproic Acid, Fludarabine - Hematological Malignancy, Acute Leukemia in Remission | Phase 1 | Completed | Alla Keyzner | 7 | 2019-02-21 | 2021-05-24 |
| Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion - Multiple Myeloma, CLL | Phase 1 | Completed | Noah Merin | 20 | 2018-07-18 | 2024-11-12 |
Showing 20 of 50. Sign in to see all of them.
Leukemia, Myeloid, Acute (18) · Multiple Myeloma (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Myelodysplastic Syndromes (12) · Leukemia, Myelomonocytic, Chronic (11) · Hodgkin Disease (10) · Lymphoma, Non-Hodgkin (8) · Leukemia (7) · Leukemia, Biphenotypic, Acute (7) · Lymphoma (7) · Anemia, Refractory, with Excess of Blasts (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Myeloproliferative Disorders (6) · Hematologic Neoplasms (5) · Anemia, Sickle Cell (4)
Fred Hutchinson Cancer Center (18) · M.D. Anderson Cancer Center (6) · Columbia University (3) · City of Hope Medical Center (2) · Mayo Clinic (2) · Ossium Health, Inc. (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Washington University School of Medicine (2) · Alice Bertaina (1) · Alla Keyzner (1) · Case Comprehensive Cancer Center (1) · Keio University (1) · Masonic Cancer Center, University of Minnesota (1) · Memorial Sloan Kettering Cancer Center (1) · Nathan Denlinger (1)
United States (47) · Italy (5) · Germany (2) · Japan (1)
Brenda Sandmaier (4) · Phuong Vo (3) · David Maloney (2) · Samer Srour (2) · Alice Bertaina, MD (1) · Alla Keyzner, MD (1) · Ann Woolfrey (1) · Brenda M. Sandmaier (1) · Elizabeth Shpall, MD (1) · Filippo Milano (1) · George Georges (1) · Hans-Peter Kiem (1) · Haydar Frangoul, MD (1) · Hien K Liu, MD (1) · Hisashi Sakamaki, M.D., Ph.D. (1)
PMID 32499241, PMID 19786617, PMID 21868572, PMID 23234514, PMID 25824692, PMID 28396162, PMID 29242852, PMID 29353109, PMID 30335787, PMID 34312462, PMID 34425261, PMID 36402456
P30CA015704 (10), P01CA078902 (5), P01CA018029 (2), P01CA044991 (2), P01CA015396 (1), P01CA049639 (1), P01CA148600 (1), P01HL122173 (1), P30CA015083 (1), P30CA033572 (1), P30CA043703 (1), R01AI041721 (1), R01CA061508 (1), R44CA192601 (1)